Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine (VCIV) to Prevent Culture Confirmed Influenza Infection (CCII)

NCT00566345 is registered in ClinicalTrials.gov with Alachua Government Services, Inc. as lead sponsor.

NCT NCT00566345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00566345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine (VCIV) to Prevent Culture Confirmed Influenza Infection (CCII)
Lead sponsor
Alachua Government Services, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2007
Completion date
June 30, 2008
Enrollment
3,670 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

influenza